In order to fully transform excellent scientific research results into productivity that can bring economic benefits, BII INatural Biotech gained the exclusive license for Lactobacillus plantarum CN2018 from Jiangnan University and held an authorization signing ceremony. This anti-H. pylori infection Lactobacillus plantarum was rigorously selected from fermented food by the scientific research team of Jiangnan University.
Anti-H. pylori strain has a wide range of application prospects in China, whose infection rate is up to 59% with nearly 700 million people infected. Looking forward, the market size of H. pylori infection treatment drugs in China will continue to expand at a CAGR of 17.2% from 2022-2027, with the market size expected to reach nearly RMB 69 billion yuan (USD $10.2 billion) by 2027. (Source: news.sina)
Visit HPA-China’s Information Hub, CLICK HERE